|
Cell Signaling Technology Inc
anti pan ampar Anti Pan Ampar, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti pan ampar/product/Cell Signaling Technology Inc Average 93 stars, based on 1 article reviews
anti pan ampar - by Bioz Stars,
2026-04
93/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
claudin2 Claudin2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/claudin2/product/Cell Signaling Technology Inc Average 93 stars, based on 1 article reviews
claudin2 - by Bioz Stars,
2026-04
93/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti glun1 Anti Glun1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti glun1/product/Cell Signaling Technology Inc Average 95 stars, based on 1 article reviews
anti glun1 - by Bioz Stars,
2026-04
95/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti glua2 Anti Glua2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti glua2/product/Cell Signaling Technology Inc Average 96 stars, based on 1 article reviews
anti glua2 - by Bioz Stars,
2026-04
96/100 stars
|
Buy from Supplier |
|
R&D Systems
anti glua2 Anti Glua2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti glua2/product/R&D Systems Average 94 stars, based on 1 article reviews
anti glua2 - by Bioz Stars,
2026-04
94/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
glua2 Glua2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/glua2/product/Cell Signaling Technology Inc Average 95 stars, based on 1 article reviews
glua2 - by Bioz Stars,
2026-04
95/100 stars
|
Buy from Supplier |
|
Proteintech
glua2 ![]() Glua2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/glua2/product/Proteintech Average 94 stars, based on 1 article reviews
glua2 - by Bioz Stars,
2026-04
94/100 stars
|
Buy from Supplier |
|
Addgene inc
pci sep glua2 catalog 24001 58 ![]() Pci Sep Glua2 Catalog 24001 58, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/pci sep glua2 catalog 24001 58/product/Addgene inc Average 93 stars, based on 1 article reviews
pci sep glua2 catalog 24001 58 - by Bioz Stars,
2026-04
93/100 stars
|
Buy from Supplier |
Journal: Frontiers in Immunology
Article Title: Hyperammonemia increases the release of pathological extracellular vesicles from monocytes by impairing lysosomal function and autophagy through the TNFα–cAMP–PKA–LC3 pathway
doi: 10.3389/fimmu.2025.1724800
Figure Lengend Snippet: Ex vivo incubation with EV from monocytes of hyperammonemic rats (HA-M-EV) induces TrkB–NR2B–GluA1–GluA2 pathway activation in hippocampal slices from control rats. Protein content of (A) TrkB (n= 8-18) and membrane expression of (B) TrkB (n= 4-14), (C) NR2B (n= 7-16), (D) NR2A (n= 6-22), (E) GluA2 (n= 5-13), and (F) GluA1 (n= 6-18) in hippocampal slices, assessed by Western blot. For the analysis of membrane expression, the sections were incubated in the presence (+) or absence (−) of the cross-linker BS3. Samples in the absence of BS3 represent the total amount of each protein, whereas samples incubated in the presence of BS3 represent the non-membrane fraction of each protein. Representative images of the blots of each protein are shown. All data are presented as mean ± SEM. Statistical analysis was determined using four separate one-way ANOVAs, each comparing the four baseline groups (C, HA, C-M-EV, and HA-M-EV) with one of the treatment groups (C-M-EV + Forsk, HA-M-EV + PKAi, C-M-EV + TNFα, or HA-M-EV + aTNFα). One-way ANOVA followed by Fisher’s post-hoc tests were performed to compare all groups. Values significantly different from the C group are indicated by asterisk (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001), values significantly different from the C-M-EV group are indicated by a (a=p<0.05, aa=p<0.01, aaa=p<0.001, aaaa=p<0.0001), and values significantly different from HA-M-EV group are indicated by b (b=p<0.05, bb=p<0.01, bbb=p<0.001, bbbb=p<0.0001).
Article Snippet: The hippocampal slices were homogenized and analyzed by Western blot as described above, using the following primary antibodies: GluaA1 (Glutamate A1 Subunit of Ampa Receptors, 1:1,000, Millipore, #04-855),
Techniques: Ex Vivo, Incubation, Activation Assay, Control, Membrane, Expressing, Western Blot
Journal: Frontiers in Immunology
Article Title: Hyperammonemia increases the release of pathological extracellular vesicles from monocytes by impairing lysosomal function and autophagy through the TNFα–cAMP–PKA–LC3 pathway
doi: 10.3389/fimmu.2025.1724800
Figure Lengend Snippet: Schematic representation of the proposed mechanism by which (1) hyperammonemia induces the formation of pathological EV containing TNFR1-TNFα in monocytes, (2) how TNFα and PKA modulate this process, and (3) how these EV induce pathological effects in the hippocampus. Hyperammonemia increases TNF α and activation of its receptor TNFR1 in monocytes, leading to activation of adenylate cyclase and increased cAMP levels and PKA activation. PKA alters both LC3, leading to increased lysosomal pH and impaired expression of lysosomal proteins such as cathepsin-L and LAMP2. This results in lysosomal dysfunction and altered autophagic flux enhances the release from multivesicular bodies (MVBs) of EV containing increased levels of TNFR1 and TNFα. These pathological HA-M-EV enhance activation of the TNFα–TNFR1–S1PR2–IL-1β–BDNF pathway and the TrkB–NR2B–GluA1–GluA2 pathway in hippocampal slices from control rats, inducing neuroinflammation and altered glutamatergic neurotransmission. All these effects are reversed by blocking TNFα with anti-TNFα or inhibiting PKA with H69 in the cultures of monocytes from hyperammonemic rats (green symbols). Activation of TNFR1 with recombinant TNFα (rTNFα) or of adenylate cyclase with forskolin in monocyte cultures from control rats induce essentially the same effects (red arrows). This figure was created using Biorender.com .
Article Snippet: The hippocampal slices were homogenized and analyzed by Western blot as described above, using the following primary antibodies: GluaA1 (Glutamate A1 Subunit of Ampa Receptors, 1:1,000, Millipore, #04-855),
Techniques: Activation Assay, Expressing, Control, Blocking Assay, Recombinant